Biology
Engineered Bacteriophages for Targeted Antibiotic-Resistant Infection Treatment
Quick fact
Some engineered phages can be programmed with CRISPR-Cas to cut the DNA of antibiotic-resistant bacteria, effectively disarmoring them.
Why this is interesting
You've probably heard of antibiotics, but what if tiny viruses could be the next weapon against deadly superbugs?
Read the full explanation
Understanding Engineered Bacteriophages for Targeted Antibiotic-Resistant Infection Treatment
Bacteriophages (or 'phages') are viruses that specifically infect bacteria. They are like tiny, targeted missiles that only attack certain bacterial strains, leaving other bacteria and human cells unharmed. Naturally occurring phages have been used in some countries for decades (phage therapy). However, naturally occurring phages may not always be effective against a particular resistant bacterium. By engineering phages, scientists can alter their genetic material to broaden their host range, make them more deadly, or even use them to deliver CRISPR systems that disrupt the bacteria's defense mechanisms. This approach is highly targeted compared to broad-spectrum antibiotics, which kill many bacteria, including beneficial ones.
A deeper explanation
The mechanism of engineered phage therapy begins with the phage's inherent specificity: it recognizes and binds to receptors on the bacterial cell surface. After binding, the phage injects its genetic material. For engineered phages, this genetic material may include genes that enhance bacterial killing, or it may encode a CRISPR-Cas system that targets a specific gene, such as one that confers antibiotic resistance. Once inside the bacterial cell, this system can cut the bacterial chromosome at that specific site, causing cell death or re-sensitizing the bacterium to antibiotics. Engineering also allows for the removal of genes that could cause toxicity or transfer harmful genes between bacteria. This targeted approach has profound implications: it can treat infections that are otherwise untreatable, preserve a patient's microbiome, and potentially reduce the development of resistance. The main challenge lies in the need to quickly engineer phages for each specific bacterial strain, but advances in synthetic biology are making this process faster and more automated.